Photomicrograph of adenocarcinoma of endometrium in a biopsy from a patient with abnormal bleeding. Credit: David A Litman / Shutterstock.com.

Hutchmed has secured breakthrough therapy designation from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for a combination of fruquintinib and sintilimab (a PD-1 antibody) to treat advanced endometrial cancer (EMC).

This therapy is intended for patients with advanced EMC who have pMMR tumours [which have intact DNA mismatch repair] and who have failed at least one line of platinum-based therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Fruquintinib is a selective and potent oral inhibitor of vascular endothelial growth factor receptor, while sintilimab is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Eli Lilly and Innovent Biologics. Sintilimab is sold as TYVYT (sintilimab injection) in China.

A clinical trial for potential registration of the combination therapy in Chinese patients with previously treated advanced EMC has now concluded enrolment.

Hutchmed has enrolled 142 patients in the open-label and multicentre trial, which will assess the efficacy and safety of the combination of fruquintinib and sintilimab.

See Also:

The trial’s primary endpoint is an independent review committee-assessed objective response rate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its secondary points are overall survival, progression-free survival, disease control rate and pharmacokinetic assessments.

Positive trial results could result in an NMPA submission for regulatory approval in the treatment setting in the first half of 2024.

Hutchmed is also involved in the development of fruquintinib in China to treat multiple solid tumours, along with anti-PD-1 monoclonal antibodies.

The company markets fruquintinib within the country in partnership with Eli Lilly. Takeda Pharmaceutical holds a licence to market the drug outside China.